Dhanvanthri S. Deevi
About
In The Last Decade
Dhanvanthri S. Deevi
18 papers receiving 838 citations
Peers
Comparison fields: 5 of 74
- Molecular Biology 429
- Oncology 289
- Complementary and alternative medicine 241
- Organic Chemistry 201
- Pulmonary and Respiratory Medicine 117
Countries citing papers authored by Dhanvanthri S. Deevi
This map shows the geographic impact of Dhanvanthri S. Deevi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dhanvanthri S. Deevi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dhanvanthri S. Deevi more than expected).
Fields of papers citing papers by Dhanvanthri S. Deevi
This network shows the impact of papers produced by Dhanvanthri S. Deevi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dhanvanthri S. Deevi. The network helps show where Dhanvanthri S. Deevi may publish in the future.
Co-authorship network of co-authors of Dhanvanthri S. Deevi
This figure shows the co-authorship network connecting the top 25 collaborators of Dhanvanthri S. Deevi. A scholar is included among the top collaborators of Dhanvanthri S. Deevi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dhanvanthri S. Deevi. Dhanvanthri S. Deevi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC. | 20 |
| 2 | Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models. | 2 |
| 3 | 1 | |
| 4 | 40 | |
| 5 | 50 | |
| 6 | Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models. | 8 |
| 7 | 2 | |
| 8 | 2 | |
| 9 | 32 | |
| 10 | 43 | |
| 11 | 127 | |
| 12 | 3 | |
| 13 | 39 | |
| 14 | 266 | |
| 15 | 17 | |
| 16 | 33 | |
| 17 | 141 | |
| 18 | 58 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.